https://www.selleckchem.com/products/epz-6438.html
On multivariate analysis, PSA doubling time (PSADT) (0-3months) at baseline, number of bone metastases (≥ 2, and treatment line of Ra-223 (4th-5th line) remained significantly correlated with the poor OS (HR 4.354, P = 0.003; HR 2.855, P = 0.020; and HR 4.871, P = 0.001, respectively). Our study demonstrated that a shorter PSADT, a heavier volume of bone metastases, and a later treatment line before Ra-223 are poor prognostic factors for mCRPC patients. These newly discovered risk factors may help select patients who potentially have
Like
Comment
Share
